The HapOnco® CorePanel™ NGS Testing KIT targets 136 core genes recommended by NCCN guidelines and linked to solid tumor development. It includes an integrated MSI status assessment. The panel offers comprehensive coverage for cancers including lung, gastrointestinal, liver, gallbladder, pancreatic, breast, gynecological, and urological cancers. The panel provides reliable mutation insights to guide tumor-targeted therapies, immunotherapies, and cancer progression analysis

The HapOnco® StarPanel™ covers the full coding regions of 574 genes and partial coding/non-coding regions of 752 genes. It incorporates NCCN-recommended Class I and II genes and those linked to FDA-approved targeted therapies. This advanced panel is suited for clinical trial enrollment, rare mutation detection, and drug resistance research to guide precision oncology treatments